The Peptidylglycine α‐Amidating Monooxygenase (PAM): A Novel Prodrug Strategy for Amidoximes and N‐Hydroxyguanidines?

Citations Over TimeTop 21% of 2009 papers

Abstract

“Pro” active: The peptidylglycine α-amidating monooxygenase (PAM) is introduced as a novel bioactivating enzyme of O-carboxymethylamidoximes and N-hydroxyguanidines—prodrug analogues of amidines and guanidines, respectively. Proof-of-concept is demonstrated in vitro with model compounds, as well as the antiprotozoic agent pentamidine. Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Related Papers

• → Prodrugs to Codrugs(2017)3 cited
• → Concept of Prodrug(2015)1 cited
• → The dinitrobenzamide mustard prodrugs, PR-104A and SN27686, for use in a novel MNDEPT cancer prodrug therapy approach(2023)1 cited
• The progress of antitumor prodrug in target tumor therapy(2007)
• → Use of prodrugs in cancer therapy - A Review(2020)